Last completed funding round put valuation at $400 million.

Funding raise validated valuation of $35 million.

Topped $20 million in annual revenue and growing.

Topped $15 million valuation and featured at international investor conferences.

Largest trade, start up, and funding organization in the state of Washington.

In the process of exiting.

Offices in Denver and Albuquerque.--Funded startup through Angels and Investment Funds--The next generation static hosting platform. All the security, speed, and ease you expect from static hosting but also with the tools and functions to take your site to the next level.Our platform provide designers and developers with a cutting edge platform to deliver fast, highly secure, and robust websites and applications. By integrating server-less architecture and JavaScript workflows, BowTie removes the instability and insecurity of legacy content management systems (like WordPress). The result is a platform used by agencies and freelancers across the country to deliver faster, safer, lower maintenance web experiences.www.BowTie.io

Key responsibilities include:--Alignment and leadership of the Product and Dev, Production, and Strategy teams with direct management of the Directors for each.--Directly responsible to the CEO and COO for strategic planning, industry insights, and operational scaling for the company as well as overall customer targeting strategy.--Develop and execute company-wide strategic initiatives for product launches and investor interest.--Active participant in corporate responsibility and outreach programs.--Quoted in Wall Street Journal (and picked up by MarketWatch, Yahoo!, and others) on @Pay and payment industry: http://online.wsj.com/article/PR-CO-20130502-913950.html?mod=googlenews_wsj

--Acquired by Groupon--LivingSocial is the e-commerce source for discovering and purchasing valuable local experiences.Key Responsibilities/Outcomes:--Division's Operations leader with direct management of Operations Improvement Team, Project Management Team, Business Solutions/Strategy Team, and Analytic Insights Team with overall responsibility of developing and driving division level operations and strategy.--Enabled the division's strong portfolio of markets and diverse products delivering an average of 31.8% revenue growth month-over-month during critical quarters.--Lead designer and program owner of company strategic initiatives plan designed to spur growth of key company division of over 450 people, streamline operations, and accelerate revenue generation.--Lead negotiator in multiple value creating company-to-company contract and partnership tie ups positively impacting all major US markets, and lead operations negotiator on multi-divisional contract negotiation resulting in partnership necessary to launch new product offerings and a new multi-million dollar business group.--Program owner of large scale multi-division financial and operations alignment of a $51 million business providing the first and most robust insights package to date for future direction setting.--Member of company wide Operations Leadership Team and Entertainment (Adventures, 918, and Live Events businesses) Leadership Team.

--Acquired by GlaxoSmithKline for $3.6 billion--Human Genome Sciences, Inc. is a leading mid-sized biotech company with strong core strengths in the areas of immunology and oncology, among others. I am responsible providing day-to-day as well as long term finance and strategic support to several leading assets in the immunology therapeutic area.Key Responsibilities/Outcomes;--Lead finance alliance management of key external collaboration programs and partners (totaling over $20 million in peak annual budget) with general business responsibilities including financing, strategic planning, operations planning, and crisis management and resolution.--Provide data gathering and analysis of future business development opportunities designed to fill mid-stage portfolio opportunities and minimize long-range product pipeline volatility.--Management of complete Development (R&D) programs budget of over $34 million and management of 45% of clinical programs budget of $55.7 million including strategic planning, forecasting, and opportunity identification.

My role with Pfizer spanned various parts of the business including strategic initiatives and financial management. My responsibilities have been diverse and included;Emerging Markets Finance Group--Lead finance member of the Medical Development Team’s Leadership Team (MDT-LT), an 8 person group responsible for coordinating commercial, clinical, and medical development in all Emerging Markets.--Management of Global Access finance responsible for executing against "tip of the spear" market entry opportunities that establishes Pfizer’s presence in new and novel markets.Emerging Markets New Business Group--Provided business development activities for 2 different company initiatives totaling nearly $400 million in total value including financial valuation, competitive analysis, and strategic framing of future negotiations resulting in major new generics projects that are core to Pfizer’s short and long term strategy.--Managed two global regions with 8 countries (forecasted with peak revenues of $2.3 billion) as the global commercial lead responsible for launch of molecules and partnerships including oversight of all functional areas from legal and manufacturing to commercial assessment and launch operations.Corporate Audit Group--Managed, on-site in various high potential markets, contractor and supplier interaction evaluations to ensure compliance with local and US laws, corporate policy, as well as ensure efficient resource usage including a full review of the acquisition integration reserve totally over $112 million.Primary Care and Oncology BUs--Provided primary financial analyst support to Viagra and Inspra assets on the research side overseeing over $14.3 million in total spend spanning all facets of clinical trials work through Phase IV.--Managed domestic clinical accruals monthly, overseeing over $225 million from all Pfizer assets and instituted process improvements decreasing hands on time by 75% without sacrificing accuracy.

I held the position of Summer Associate (MBA Intern) during the summer between my first and second year of business school. While here I worked on three large projects. The majority of my time was devoted to a financial and strategic restructuring of some of Pfizer's legal entities. Second, I provided modeling and financial support for a new distribution strategy being roled out in Southeast Asia. Finally, I supported the Asia finance team in management and roll-up of end of quarter and end of year financials from Asian markets.Key Accomplishments:-Developed valuation framework and impact model to describe and analyze new growth opportunities in India resulting in discovery of $17 million in recaptured value through in-country entity restructuring. -Constructed a "playbook" of multiple financial and strategic models to assess upside value of new market entry and new trade channel mixes in Southeast Asia resulting in several new market possibilities and potential incremental upside of $10-15 million in sales depending on the market. -Revised country reporting to include new strategic initiatives leading to a more granular view of sales. -Liaised with external consultants to facilitate implementation of project recommendations.

-Managed lab of 3 researchers, support personnel, project budget, and $20,000 yearly resource allocation. -Decreased average monthly costs by 30% year-over-year through development of system of standing vendor contracts and establishment of a database for budget and supplies. -Designed and executed standalone scientific experiments resulting in multiple peer reviewed publications.Selected Publications:-HMGA1 levels influence mitochondrial function and mitochondrial DNA repair efficiency. Mao L, Wertzler KJ, Maloney SC, Wang Z, Magnuson NS, Reeves R. Mol Cell Biol. 2009 Oct;29(20):5426-40. Epub 2009 Aug 17.-High-mobility group A1 proteins inhibit expression of nucleotide excision repair factor xeroderma pigmentosum group A. Adair JE, Maloney SC, Dement GA, Wertzler KJ, Smerdon MJ, Reeves R. Cancer Res. 2007 Jul 1;67(13):6044-52.-Gene-specific nucleotide excision repair is impaired in human cells expressing elevated levels of high mobility group A1 nonhistone proteins. Maloney SC, Adair JE, Smerdon MJ, Reeves R. DNA Repair (Amst). 2007 Sep 1;6(9):1371-9. Epub 2007 May 30.-Nuclear HMGA1 nonhistone chromatin proteins directly influence mitochondrial transcription, maintenance, and function. Dement GA, Maloney SC, Reeves R. Exp Cell Res. 2007 Jan 1;313(1):77-87. Epub 2006 Sep 22.

Provided research support for lab strategic initiatives of agriculturally significant crop genetic manipulations. Jointly supervised support technician staff.Selected Publications:-Construction and expression of sugar kinase transcriptional gene fusions by using the Sinorhizobium meliloti ORFeome. Humann JL, Schroeder BK, Mortimer MW, House BL, Yurgel SN, Maloney SC, Ward KL, Fallquist HM, Ziemkiewicz HT, Kahn ML. Appl Environ Microbiol. 2008 Nov;74(21):6756-65. Epub 2008 Sep 12.-Development of a functional genomics platform for Sinorhizobium meliloti: construction of an ORFeome. Schroeder BK, House BL, Mortimer MW, Yurgel SN, Maloney SC, Ward KL, Kahn ML. Appl Environ Microbiol. 2005 Oct;71(10):5858-64.